Successful DAA therapy may lead to cognitive improvement in several domains in HCV-infected patients.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.
Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.
Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985
In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.
Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.
Elbasvir and grazoprevir, taken in combination for 12 weeks, successfully treated virologic response in patient with hepatitis C genotype 1b.
Once daily glecaprevir-pibrentasvir for 8 or 12 weeks successfully treated HCV genotype 1 and 3.
Patients with chronic HCV with a sustained virologic response were more likely to have a reduced progression of liver fibrosis.
Hepatitis B and hepatitis C may increase mortality risks in HIV patients.
Hepatitis C treatment improves outcomes and experiences for patient and provider.
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America have added updates to the hepatitis C guidelines to include kidney transplant, pregnant, and pediatric patients.
The results show no evidence to support a hypothesis of differential impact of interferon and direct-acting antiviral-based cure on risk for HCC occurrence and recurrence.
Primary care providers and nurse practitioners achieve the same sustained virologic response rates as specialists.
The prompt increased hepatitis C screening rates among baby boomers in primary care by 5-fold.
HIV, hepatitis B, and hepatitis C infections are more common among individuals with severe mental illness.
The update includes 30 new medicines for adults and 25 for children and groups antibiotics into 3 distinct categories.
Hepatitis C treatment in HIV coinfection cases is effective with standardized nurse and pharmacist support for patients in an urban clinic.
Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of HCV.
Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.
Patients with chronic HCV infection who have achieved a sustained virologic response with treatment may still be at risk for complications such as hepatocellular carcinoma.
Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.
Harvoni and Sovaldi have been approved for pediatric patients with HCV genotypes.
Regimens for the treatment of hepatitis C that included ribavirin had more mild or moderate adverse events than those without.